Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTristel Regulatory News (TSTL)

Share Price Information for Tristel (TSTL)

Share Price is delayed by 15 minutes
Get Live Data
387.50    -5.00 (-1.27%)
Bid:
380.00
Ask:
395.00
Spread: 15.00 (3.947%)
Market Cap: £185.99m
TSTL Live PriceLast checked at - London Stock Exchange

Intraday Tristel Share Chart

Result of AGM

11 Dec 2025 11:54

RNS Number : 2296L
Tristel PLC
11 December 2025
 

TRISTEL plc

("Tristel" or the "Company")

 

Result of AGM

 

Tristel plc (AIM: TSTL), the manufacturer of infection prevention products, announces that at the Annual General Meeting ("AGM") held earlier today, all resolutions were duly passed.

 

Resolution 1, which sought to receive and adopt the Company's annual accounts for the financial year ended 30 June 2025, together with the Directors' report, the Directors' remuneration report and the auditor's report on those accounts, passed with 59% of votes cast. With respect to this resolution the Company received notice from one of the proxy voting advisers that they were recommending investors to vote against it, due to lack of a separate vote for remuneration policy and the level of loss of office payment to a former Director accompanied by limited disclosure.

 

Resolution 1 has been discussed with several of the institutional shareholders and within the Board. The Board undertakes that it will ensure any necessary future disclosure complies with best practice, along with committing to put the remuneration policy to a separate vote at future AGMs, in line with QCA guidance.

 

The Company would like to reiterate that it takes its shareholder responsibilities seriously and has a clear focus on striving for governance best practice, sharpening capital allocation and driving sustainable growth.

 

The results of the AGM will be made available on the Company's website: https://tristelgroup.com/invest/annual-general-meeting-agm/

 

For further information please contact:

 

Tristel plc

Via Walbrook PR

Matt Sassone, Chief Executive Officer

www.investors.tristel.com

Anna Wasyl, Chief Financial Officer

Walbrook PR Ltd

Tel: 020 7933 8780 or tristel@walbrookpr.com

Paul McManus / Lianne Applegarth / Anna Dunphy 

Mob: 07980 541 893/ 07584 391 303/ 07876 741 001

Cavendish Capital Markets Ltd

Tel: 020 7220 0500

Geoff Nash / Callum Davidson / Trisyia Jamaludin (Corporate Finance)

Sunila de Silva (Corporate Broking) / Louise Talbot (Sales)

 

 

About Tristel plc

 

Tristel plc is a global infection prevention company focussed on the manufacture and supply of products using its unique proprietary chlorine dioxide (ClO2) chemistry. The Company is a market leader in manual decontamination of medical devices, supplying hospitals under the Tristel brand, and under the Cache brand provides products for sporicidal surface disinfection, a more sustainable alternative to commonly used pre-wetted plastic wipes.

 

Tristel's head office and manufacturing facility is located in Snailwell, near Cambridge, and operates globally employing approximately 270 people across 16 subsidiaries selling into 40+ countries. The Company targets double digit revenue growth annually and an EBITDA margin of at least 25% and the business is profitable, with no debt and has a progressive dividend policy.

 

The Company has been listed on the London Stock Exchange's AIM market since 2005 (AIM: TSTL).

 

For more information about Tristel's product range please visit: https://tristel.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RAGFLFELFVLLLIE
Date   Source Headline
7th Jul 20263:04 pmRNSHolding(s) in Company
7th Jul 20267:00 amRNS-RAPIC26 Annual Conference attendance
17th Jun 20267:00 amRNSAppointment of CEO
16th Jun 202612:00 pmRNSHolding(s) in Company
10th Jun 20267:00 amRNSExercise of Share Options & Total Voting Rights
13th May 202610:10 amRNSExercise of Share Options and Total Voting Rights
5th May 20267:00 amRNSExercise of Share Options and Total Voting Rights
20th Apr 20262:28 pmRNSHolding(s) in Company
20th Apr 20268:20 amRNSHolding(s) in Company
23rd Mar 20267:00 amRNSDirector/PDMR Shareholding
18th Mar 20267:00 amRNS-RConference attendance at ShareSoc Leeds
17th Mar 20265:13 pmRNSHolding(s) in Company
3rd Mar 20264:04 pmRNSPCA Dealing
2nd Mar 20267:00 amRNSHalf-year Financial Report
12th Feb 20267:00 amRNSExercise of Share Options and Total Voting Rights
6th Feb 202611:56 amRNSExercise of Share Options and Total Voting Rights
6th Feb 20267:00 amRNSNotice of Results
22nd Jan 20267:00 amRNSPositive H1 Trading Update & Directorate Change
8th Jan 20263:10 pmRNSExercise of Share Options and Total Voting Rights
12th Dec 202510:37 amRNSDirector/PDMR Shareholding
12th Dec 20259:19 amRNSExercise of Share Options and Total Voting Rights
11th Dec 202511:54 amRNSResult of AGM
11th Dec 20257:00 amRNSAGM Statement
24th Nov 202512:28 pmRNSDirector Option Grant
24th Nov 20257:00 amRNSUpdated US guidelines for high level disinfection
18th Nov 20257:00 amRNSNotice of AGM & Posting of Annual Report &Accounts
12th Nov 202511:33 amRNSHolding(s) in Company
31st Oct 20254:11 pmRNSHolding(s) in Company
31st Oct 20252:12 pmRNSHolding(s) in Company
22nd Oct 20254:56 pmRNSHolding(s) in Company
16th Oct 20254:00 pmRNSExercise of Share Options and Total Voting Rights
13th Oct 202512:00 pmRNSExercise of Share Options and Total Voting Rights
13th Oct 20257:00 amRNSFinal Results
9th Oct 202510:06 amRNSExercise of Share Options and Total Voting Rights
25th Sep 20257:00 amRNSVISICLEAN Product Launch
16th Sep 20257:00 amRNSNotice of Preliminary Results
11th Sep 20257:00 amRNSExercise of Share Options and Total Voting Rights
1st Sep 20257:00 amRNSConfirmation of CFO Appointment
21st Aug 20253:56 pmRNSHolding(s) in Company
18th Aug 202512:15 pmRNSExercise of Share Options and Total Voting Rights
6th Aug 20254:05 pmRNS-RCapital Markets Day video update
29th Jul 20257:00 amRNSTrading update
24th Jul 20257:00 amRNSConfirmation of Investor presentations
17th Jul 20257:00 amRNSAppointment of Chief Financial Officer
4th Jul 20251:02 pmRNSHolding(s) in Company
26th Jun 20257:00 amRNS-RAPIC25 Annual Conference attendance
2nd Jun 20257:00 amRNSInvestor Presentations & Notice of Trading Update
30th May 20257:00 amRNSHolding(s) in Company
28th May 20257:00 amRNS-RConference attendance at Mello2025 Investor event
16th May 20257:00 amRNSExercise of Share Options and Total Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.